Retrospective study analyzing the impact of dose delays and reductions on toxicity and progression free survival (PFS) in patients receiving palbociclib

Trial Profile

Retrospective study analyzing the impact of dose delays and reductions on toxicity and progression free survival (PFS) in patients receiving palbociclib

Completed
Phase of Trial: Phase IV

Latest Information Update: 11 Jan 2018

At a glance

  • Drugs Palbociclib (Primary) ; Fulvestrant; Letrozole
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Jan 2018 New trial record
    • 09 Dec 2017 Results analyzing the impact of dose delays and reductions on toxicity and progression free survival (PFS) in patients receiving palbociclib presented at the 40th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top